Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;6(6):599-603.
doi: 10.1093/ckj/sft116. Epub 2013 Sep 23.

Do biologic markers predict cardiovascular end points in diabetic end-stage renal disease? A prospective longitudinal study

George P Bayliss  1 , Larry A Weinrauch  2 , Ray E Gleason  3 , Annette T Lee  4 , John A D'Elia  2
Affiliations

Do biologic markers predict cardiovascular end points in diabetic end-stage renal disease? A prospective longitudinal study

George P Bayliss et al. Clin Kidney J. 2013 Dec.

Abstract

Background: Diabetic patients on hemodialysis are at high risk of death from cardiovascular disease, and research has suggested that various biologic markers of inflammation, oxidative stress and hemostasis may give added value to clinical information for predicting cardiovascular event (CVE)-free survival. This information could be particularly important in evaluating this population for renal transplant, given the scarcity of organs. We hypothesized that in diabetic patients undergoing renal replacement therapy (RRT) these biologic markers would prove useful in predicting event-free follow-up in a prospective study.

Methods: One hundred and fifty diabetic (76 type 1, 74 type 2) and 27 non-diabetic stable RRT patients were followed for 0.04-13.69 years for CVE (myocardial infarction, coronary arterial intervention, peripheral arterial bypass or amputation, cerebrovascular accident or carotid artery intervention), cardiac and all-cause mortality. Measured biologic markers of inflammation included the following: Il-6, C reactive protein, fibrinogen; of hemostasis: fibrinogen, plasminogen activator inhibitor (PAI), fibrinolytic activity, von Willebrand factor VII (vWF), platelet-selectin, viscosity and of oxidative stress: advanced glycated end products and antibody to oxidized low-density lipoprotein. For each, upper versus lower tertiles were compared for duration of event-free follow-up.

Results: Cardiovascular events prior to study entry occurred in 51.3% of DM1, 54.0% of DM2 and 25.9% of DM0 patients. Subsequent cardiovascular events were noted in 31.6% of DM1, 45.9% of DM2 and 11.1% of DM0 patients. All mean levels of biologic markers at baseline were abnormal (P < 0.05).

Conclusions: In this RRT population, all biologic marker levels except PAI did not improve clinical prediction of events.

Keywords: biologic markers; cardiovascular events; diabetes; plasminogen activator inhibitor; renal replacement therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. D'Elia JA, Weinrauch LA, Gleason RE, et al. Risk factors for thromboembolic events in renal failure. Int J Cardiol. 2005;101:19–25. doi:10.1016/j.ijcard.2004.03.007. - DOI - PubMed
    1. Clauss A. Gerinnunphysiologisiche schnellmethode zur bestimmung des fibrinogens. Acta Hematol. 1957;17:237–247. doi:10.1159/000205234. - DOI - PubMed
    1. Lipinski B, Lipinska I. Effect of magnesium on fibrin formation from lower molecular weight (LMKW) fibrinogen. Magnes Res. 2000;13:233–237. - PubMed
    1. Penny W, Weinstein M, Salzmann E. Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation. 1991;83:1630–1636. doi:10.1161/01.CIR.83.5.1630. - DOI - PubMed
    1. Brakman P. A standard fibrin plate method and fibrinolytic assay of plasminogen. In: Hokema P, Scheltma R, editors. Fibrinolysis. Amsterdam: Elsevier; 1967. pp. 1–124.